Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Nanoparticulate statin formulations and novel statin combinations

Inactive Publication Date: 2011-02-03
ELAN PHRMA INT LTD
View PDF99 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0017]Other embodiments of the invention include, but are not limited to, nanoparticulate statin compositions which, as compared to conventional non-nanoparticulate formulations of the same statin, preferably have one or more of the following properties: (1) smaller ta

Problems solved by technology

Poor bioavailability is a significant problem encountered in the development of pharmaceutical compositions, particularly those containing an active ingredient that is poorly soluble in water.
The '684 patent does not teach nanoparticulate compositions of statins.
Additionally, these drugs lower serum triglyceride levels, whic

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0168]The purpose of this example was to prepare nanoparticulate dispersions of lovastatin, and to test the prepared compositions for stability at varying temperatures.

[0169]Four formulations of lovastatin were milled, as described in Table 1, by milling the components of the compositions under high energy milling conditions in a DYNO®-Mill KDL (Willy A. Bachofen AG, Maschinenfabrik, Basle, Switzerland) for 2 to 3 hours until the desired particle size was achieved.

[0170]Formulation 1 comprised 5% (w / w) lovastatin, 1.25% (w / w) Hydroxypropylcellulose, super-low viscosity grade (HPC-SL), and 0.05% (w / w) dioctyl sodium sulfosuccinate (DOSS).

[0171]Formulation 2 comprised 5% (w / w) lovastatin, 1.25% (w / w) hydroxypropylmethylcellulose (HPMC), and 0.05% (w / w) dioctyl sodium sulfosuccinate (DOSS).

[0172]Formulation 3 comprised 5% (w / w) lovastatin, 1.25% (w / w) Povidone USP, Plasdone® K29 / 52 (PVPK29\32), and 0.05% (w / w) dioctyl sodium sulfosuccinate (DOSS).

[0173]Formulation 4 comprised 5% (w / w) ...

example 2

[0175]As described in the literature (Pharmazie, Volume 56, September 2001, p 738-740), lovastatin has a potential for oxidative degradation. To determine which of the formulations exhibited the least amount of degradants an HPLC analysis was performed on the compositions prepared in Example 1.

[0176]The method was a reversed phase HPLC method based on an existing assay method found in the literature (Pharmazie, Volume 56, September 2001, p 738-740). The results of these sample runs were compared to an active pharmaceutical ingredient (API), commercially available lovastatin, standard to determine which milled sample was least oxidized.

[0177]Analysis took place after 4-5 weeks of storage. The four different samples were compared to an API standard. For this comparison three factors were used to determine which formulation was optimal: (1) the percent lovastatin, (2) overall appearance of impurity profile, and (3) the percent area of the peak at RRT 0.87. This peak was selected was be...

example 3

[0180]The purpose of this example was to evaluate the efficacy of nanoparticulate lovastatin compositions.

[0181]New Zealand White rabbits were fed a diet enriched with 1% cholesterol for four weeks. At the four week time point the animals were maintained on a high cholesterol diet but were dosed (in the fed state) each day for a additional four week period with 6 mg / kg dose of either suspensions of Formulation #2 (Example 1) or commercially available lovastatin (Mevacor®) tablets mortarized into a crude suspension comprising the same quantities of HPMC and DOSS as Formulation #2. Placebo also comprised the same quantities of HPMC and DOSS as formulation #2.

[0182]Blood samples for total cholesterol analysis were taken at −2, 0, 2, & 4 weeks after dosing. Total change in cholesterol for each group was as follows:

[0183]1. Mevacor® mortarized tablets dosed as a liquid suspension: −17.8% (N=6) 2. Formulation #2 dosed as a liquid suspension: −23.2% (N=8) 3. Placebo dosed as a liquid suspe...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to View More

Abstract

The present invention is directed to nanoparticulate compositions comprising statin such as lovastatin or simvastatin. The statin particles of the composition have an effective average particle size of less than about 2000 nm. In another aspect of this invention, novel combinations of statins and other cholesterol lowering agents are described and methods of using same are taught.

Description

FIELD OF THE INVENTION[0001]The present invention relates to nanoparticulate compositions comprising statin, preferably lovastatin or simvastatin, and novel statin combinations. The nanoparticulate statin particles preferably have an effective average particle size of less than about 2000 nm. In another aspect, this invention includes novel combinations of statins and other cholesterol lowering agents and methods of using the same.BACKGROUND OF THE INVENTION[0002]I. Background Regarding Nanoparticulate Active Agent Compositions[0003]Nanoparticulate active agent compositions, first described in U.S. Pat. No. 5,145,684 (“the '684 patent”), are particles consisting of a poorly soluble therapeutic or diagnostic agent having adsorbed onto, or associated with, the surface thereof a non-crosslinked surface stabilizer. Many factors can affect bioavailability including the dosage form and various properties, e.g., dissolution rate of the drug. Poor bioavailability is a significant problem en...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/717A61K9/14A61K31/351A61K9/12A61K31/56A61K31/455A61K31/397A61P3/06A61P9/00A61P25/28A61K9/20
CPCA61K9/146A61K9/2077A61K9/2054A61P25/28A61P3/06A61P9/00
Inventor COOPER, EUGENE R.HOVEY, DOUGLASCARY, GRETALINDNER, MARIELIVERSIDGE, ELAINELIVERSIDGE, GARY G.RYDE, TUULA
Owner ELAN PHRMA INT LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com